{"links":{"feed":"https://www.erudio.com/reports/ea2251-nct07765433/feed.json","html":"https://www.erudio.com/reports/ea2251-nct07765433","json":"https://www.erudio.com/reports/ea2251-nct07765433.json","markdown":"https://www.erudio.com/reports/ea2251-nct07765433.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"ea2251-nct07765433"}},"request":"https://www.erudio.com/contact?report=ea2251-nct07765433"},"offer":{"cited_clinicians":3,"cited_commentary_sources":12,"verified_hcp_statements":28,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"ea2251-nct07765433"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ea2251-nct07765433","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ea2251-nct07765433","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 28 verified statements · 4 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T18:02:16.056334Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":13,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":10,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":12,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":6,"title":"Evidence maturity and additional information requested"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Country-of-origin scrutiny and access"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":3,"title":"Regulatory status, local availability and patient counseling"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":3,"title":"Pan-tumor extrapolation and class-level interest"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Cross-trial rankings and clinical value"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":10,"cited_clinicians":3,"cited_clinicians_by_role":{"physician, Medical oncology":3},"cited_physicians":3,"cited_sources":12,"claims_by_expression_type":{"comparison":1,"interpretation":8,"opinion":5,"restatement":9,"uncertainty":2,"unspecified":3},"claims_by_kind":{"limitation":1,"source_observation":27},"clinician_statements":4,"evidence_units":16,"findings":6,"organisational_accounts":4,"people_cited":5,"people_identity_verified":4,"people_total":6,"screened_sources":29,"verified_claims":28},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":3},"limitations":2,"links":{"context":1,"support":7},"ma_question":true,"named_voices":3,"passages":6,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"GI1: most speakers value active control; a clinician asks what the bispecific adds","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-a3205a5aaf691211beb7"],"clause":"a clinician asks what the bispecific adds","holders":1},"cited_claim_ids":["claim-bac1619280039ffe5983","claim-097b151d3fbfa9f352a9","claim-dcf89d91ac5363aab07f"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"7 statements from 3 speakers in 6 sources, 1 of them a podcast or video","holder_line":"2 of the 3 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician asks what the bispecific adds”"},{"cited_clinicians":0,"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":5},"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":1,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"EA2251: what speakers say","evidence_line":"8 statements from 1 speaker in 5 sources, 1 of them a podcast or video"},{"cited_clinicians":0,"id":"F2","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":3,"views":1},"limitations":3,"links":{"context":2,"support":6},"ma_question":true,"named_voices":1,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Ivonescimab in HARMONi-GI1: what speakers say","evidence_line":"5 statements from 1 speaker in 5 sources, 1 of them a podcast or video"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":2},"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":6,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"HARMONi-GI1 evidence: where speakers split on scrutiny of China-only interim data","title_holders":{"cited_claim_ids":["claim-f0a4a83cf5ca5b519a4c","claim-034133e223cbe520e8b3","claim-612d62c7205743eacba4","claim-ed0f76dc13a11168da70","claim-33bb71932c48342d05b3","claim-161eb49e75a6c21e0da8"],"clinicians":false,"holders":3,"sides":[{"cited_claim_ids":["claim-f0a4a83cf5ca5b519a4c","claim-034133e223cbe520e8b3","claim-612d62c7205743eacba4","claim-ed0f76dc13a11168da70","claim-33bb71932c48342d05b3"],"holders":2},{"cited_claim_ids":["claim-161eb49e75a6c21e0da8"],"holders":1}],"speakers":3,"view":"split"},"evidence_line":"6 statements from 3 speakers in 6 sources, 1 of them a podcast or video","holder_line":"3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other"},{"cited_clinicians":2,"id":"F5","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":4},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Ivonescimab: where speakers split on pan-tumor expectations after interim GI1","title_holders":{"cited_claim_ids":["claim-41dfeda2489a7a3c6d2b","claim-097b151d3fbfa9f352a9"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-41dfeda2489a7a3c6d2b"],"holders":1},{"cited_claim_ids":["claim-097b151d3fbfa9f352a9"],"holders":1}],"speakers":3,"view":"split"},"evidence_line":"4 statements from 3 speakers in 3 sources","holder_line":"2 of the 3 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":0,"id":"F6","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"OS hazard-ratio rankings: why a speaker weighs cancer context and options","title_holders":{"cited_claim_ids":["claim-8d52c7f48813a5b9faa4"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From finding F1 (7 statements from 3 speakers in 6 sources)","cited_claim_ids":["claim-bac1619280039ffe5983","claim-097b151d3fbfa9f352a9","claim-a3205a5aaf691211beb7","claim-0417ea83af8f0ffc98d6","claim-612d62c7205743eacba4","claim-dcf89d91ac5363aab07f","claim-848d53e9480e8bf9ad28"],"finding_ids":["F1"],"question":"What evidence do clinicians say they need on ivonescimab’s bispecific contribution and applicability beyond China before using it with chemotherapy instead of durvalumab plus chemotherapy for first-line advanced biliary tract cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers value the active-standard comparison; one clinician asks what the bispecific adds"},{"id":"section-2","level":2,"title":"Accounts give different US timing expectations; a video stresses that priority review is not approval"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"Accounts flag added toxicity; the sponsor calls the combination tolerable"},{"id":"section-5","level":3,"title":"Accounts flag immature, China-only evidence; one clinician argues for country-neutral scrutiny"},{"id":"section-6","level":3,"title":"One clinician makes an unqualified pan-tumor prediction; another challenges the leap"},{"id":"section-7","level":3,"title":"One X account cautions against equating OS-hazard-ratio rankings with treatment value"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F4","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F4","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":4}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T18:02:16.056334Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T18:15:42Z","record_hash":"773b42717a9440239d735d6b00f39cfd45920c4661880ebb9e1a47a540435a0b","release_hash":"8acb8d077dad8f4b454d4ee35d2d2e11c2ac809bfdadf963ca1e080ced8fc1a7","report_id":"erudio-nct07765433","run_id":"81c09e42-9567-46c1-98f5-489603749cd9","schema_version":"5.0","slug":"ea2251-nct07765433","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist looks to EA2251 for clarity on the bispecific’s contribution because HARMONi-GI1 lacked a PD-L1-plus-bevacizumab arm, though that capability is unproven. Direct commentary is limited; HARMONi-GI1 provides context, not outcomes from the US study. Its reported survival benefit is qualified by accounts of greater high-grade toxicity. In that context, the same oncologist questions another medical oncologist’s unconditional prediction of pan-tumor blockbuster status for ivonescimab, citing interim evidence. Final survival and quality-of-life data remained pending.","examples":[],"meta_description":"29 sources screened · 28 verified statements (4 from clinicians verified by NPI or staff page) from 12 sources · 6 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T18:15:42Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":29},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","24 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 34 sources about other trials or topics are not included.","Most substantive efficacy and safety commentary concerns HARMONi-GI1 as evidence for the same first-line decision, not outcomes observed in EA2251.","No EA2251 protocol or publication reporting its outcomes was identified in the sources reviewed for this edition. The comments therefore cannot independently resolve expectations about which treatment contribution EA2251 could isolate.","The sources include corporate communication and repeated summaries of release-derived information. Their number cannot be interpreted as a number of independent HCP opinions or as the prevalence of a view.","Only part of the relevant regulatory material was reviewed. Approval, availability and development forecasts remain dated source statements rather than a complete or current regulatory assessment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-11-10","start":"2026-08-26"},"retrieval_snapshot":"2026-11-22T17:07:03.297776Z","timeline":[{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":6,"week":"2026-W43"},{"count":2,"week":"2026-W44"},{"count":1,"week":"2026-W45"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07765433:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07765433:context","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"openfda:8baba4ea-2855-42fa-9bd9-5a7548d4cec3:20260831","quote_policy":"short_quote_link_out"},{"id":"openfda:44bcc16c-341d-49e8-a1c6-95d084667aca:20260820","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6s3umv2qdmlfgekehxgldeld-3mzdyzamtnx25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mz54asrgb22b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mtyjkyvzx22n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3myevlcnzyz2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mypktijspi26","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t5kvjzece3qgysdmwvem36xv-3myfmv6cdkm2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ydsczgdl24wfclxi62vv2m23-3mtxwo5xhdk22","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7500436608932978688","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088809874356625738:ce2a30af-88b0-4780-ab0b-81a639562c9c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092687422505017606:7020bf1c-3816-4107-8cb9-a0114eb11e89","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093369964572913775:3a5ae641-d253-447a-965b-0e2f18990f3f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094033663168024823:c615ccaa-e623-47d9-88f9-7624aad55787","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112934964442407093:53bcae6c-0f7b-435b-825d-4a6226a853e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112955039522382196:7211da0d-fcd6-400b-9b43-c0834641cd35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113239219237961900:c7b79f69-8bd5-45da-87f0-fa4611fd2c73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114391462330941540:57fa6329-8697-4d01-a1dd-bcb8e08cf107","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114401724714934556:528f7df1-86e5-43d8-bdbb-189a9b61608f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114402745406939519:033c5d21-dd59-4ad5-a51f-bd4ef94b9cf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114438328783421649:1ee8eaf7-19ab-4076-8293-d05248a6dbce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114443649362649496:d92c0014-3614-4d9e-8ad7-e35b499e84d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114472612390990240:02e2815c-ebf7-4c10-887f-4ca95d8c4ad0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114481275033821404:460f8a4e-e7d9-4f1d-ad7d-80457778f357","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114692547821928822:4c486b3c-6ca4-451b-b546-f23cdaa25064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114794214118801439:a06453f4-171a-45a3-9aab-42b2ac35ebed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115089182762684855:76655526-1968-4124-b23c-3a3df6b85ef4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118102757785690183:74e91f4c-f001-4933-a79a-e77e1fafc672","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118189206707323326:641f7aac-e2c5-42c0-a8f7-838208f4268a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118743155898204186:578eb696-45e1-47ad-b2bf-1877eda9fff8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:28KdUgJndj4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":20,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":29},"count":29,"evidence_window":{"end":"2026-11-10","start":"2026-08-16"},"retrieval_snapshot":"2026-11-22T17:07:03.297776Z","timeline":[{"count":1,"week":"2026-W33"},{"count":5,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":13,"week":"2026-W43"},{"count":4,"week":"2026-W44"},{"count":4,"week":"2026-W45"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Imfinzi"],"label":"durvalumab","slug":"durvalumab"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"ivonescimab","slug":"ivonescimab"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"reason":"Unmapped registry condition: Locally Advanced Biliary Tract Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Locally Advanced Extrahepatic Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Locally Advanced Intrahepatic Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Locally Advanced Unresectable Gallbladder Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Biliary Tract Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Extrahepatic Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Gallbladder Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Metastatic Intrahepatic Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Stage III Distal Bile Duct Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage III Intrahepatic Cholangiocarcinoma AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IV Distal Bile Duct Cancer AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","status":"unmapped"},{"reason":"Unmapped registry condition: Unresectable Biliary Tract Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Unresectable Extrahepatic Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Unresectable Intrahepatic Cholangiocarcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Biliary tract cancer","slug":"biliary-tract-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EA2251","aliases":["EA2251","Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer","A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer"],"brief_title":"Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer","collaborators":["National Cancer Institute (NCI)"],"conditions":["Locally Advanced Biliary Tract Adenocarcinoma","Locally Advanced Extrahepatic Cholangiocarcinoma","Locally Advanced Intrahepatic Cholangiocarcinoma","Locally Advanced Unresectable Gallbladder Adenocarcinoma","Metastatic Biliary Tract Adenocarcinoma","Metastatic Extrahepatic Cholangiocarcinoma","Metastatic Gallbladder Adenocarcinoma","Metastatic Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Adenocarcinoma","Unresectable Extrahepatic Cholangiocarcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"display_condition":"advanced biliary tract cancer","display_interventions":[["ivonescimab"]],"enrollment":{"count":336,"type":"ESTIMATED"},"interventions":[{"name":"Biospecimen Collection","synonyms":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Cisplatin","synonyms":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Computed Tomography","synonyms":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Durvalumab","synonyms":["Imfinzi","Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI 4736","MEDI-4736","MEDI4736"],"type":"BIOLOGICAL"},{"name":"Gemcitabine Hydrochloride","synonyms":["dFdCyd","Difluorodeoxycytidine Hydrochloride","Gemcitabine HCI","Gemzar","LY 188011","LY-188011","LY188011"],"type":"DRUG"},{"name":"Ivonescimab","synonyms":["AK 112","AK-112","AK112","Anti-PD-1/Anti-VEGF Bispecific Antibody AK112","Anti-PD-1/VEGF Bispecific Antibody AK112","PD-1/VEGF Bispecific Antibody AK112","SMT 112","SMT-112","SMT112"],"type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","synonyms":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Pembrolizumab","synonyms":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","Pembrolizumab Biosimilar SB27","QL2107","RPH 075","RPH-075","RPH075","SB 27","SB-27","SB27","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"}],"nct_id":"NCT07765433","official_title":"A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer","overall_status":"NOT_YET_RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Overall survival (OS)","timeFrame":"From date of randomization until the date of death from any cause, assessed up to 3 years"}],"registered_date":{"date":"2026-08-14","type":"ACTUAL"},"registry_last_updated":"2026-08-14","registry_url":"https://clinicaltrials.gov/study/NCT07765433","short_name":"EA2251","short_name_basis":"canonical_name","sponsor":"ECOG-ACRIN Cancer Research Group","start_date":{"date":"2027-01-11","type":"ESTIMATED"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"EA2251","type":"sponsor_study_id"},{"domain":"CTRP (Clinical Trial Reporting Program)","id":"NCI-2026-04569","type":"registry"},{"id":"U10CA180820","type":"nih"}],"study_type":"INTERVENTIONAL"}}}